You are viewing the site in preview mode
Skip to main content
| |
Overall
|
|---|
|
(N = 120)
|
|---|
|
Age, years
|
60.0 ± 10.9
|
|
Male, n (%)
|
82 (68.3)
|
|
AF duration, median (IQR)
|
24 (12–48.5)
|
|
Comorbidities, n (%)
|
|
Heart failure
|
26 (21.7)
|
|
Hypertension
|
62 (51.7)
|
|
Diabetes mellitus
|
25 (20.8)
|
|
Stroke
|
15 (12.5)
|
|
Vascular disease
|
7 (5.8)
|
|
CHA2DS2-VASc score
|
1.97 ± 1.6
|
|
AAD use prior to the ablation, n (%)
|
|
Class Ic
|
54 (45.0)
|
|
Class III
|
64 (53.3)
|
|
Echocardiographic parameters
|
|
LA dimension, mm
|
44.09 ± 5.6
|
|
LA volume index, ml/m2
|
42.00 ± 11.9
|
|
LV ejection fraction, %
|
60.52 ± 7.3
|
|
E/Em
|
10.06 ± 4.7
|
- AAD, antiarrhythmic drug; LA, left atrium; LV, left ventricle; E/Em, mitral inflow velocity/mitral annulus tissue velocity
